nach oben

Clinical & Translational Metabolism

Erschienen in:

05.02.2018 | Review Article

Effects of Bazedoxifene on Bone Mineral Density and Fracture in Post-Menopausal Osteoporotic Women: a Systematic Review and Meta-Analysis

verfasst von: Malahat Khalili, Ali Hosseinzadeh, Habib_ollah Mohammadi Kiavandani, Narges Khanjani

Erschienen in: Clinical & Translational Metabolism | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Bazedoxifene (BZA) is a selective estrogen receptor modulator that reduces the risk of fracture and improves bone mineral density in post-menopausal women with osteoporosis. The aim of the present systematic review and meta-analysis was to investigate effects of BZA on bone mineral density (BMD) and fracture in post-menopausal osteoporotic women. We searched PubMed, Cochrane Central Register of Controlled Trials, Web of Sciences, Embase, and Scopus from until November 30, 2016. All randomized controlled trials that compared the effects of BZA on BMD and the incidence of vertebral and non-vertebral fractures in post-menopausal osteoporotic women compared with a control group were eligible for inclusion. Meta-analyses were conducted to calculate relative risk (RR) with 95% confidence interval (CI) for the association of BZA and vertebral and non-vertebral fractures compared with placebo. Nine randomized clinical trials met our inclusion criteria. Studies results showed that BZA significantly improves BMD, although we were not able to pool the results. Meta-analysis showed that the pooled effect of BZD on vertebral fracture was protective and significant (RR = 0.63; 95% CI 0.48, 0.83; P = 0.001). But pooled results did not show any association between taking BZD and the incidence of non-vertebral fracture (RR = 0.97; 95% CI 0.83, 1.13; P = 0.683). Evidence suggests that bazedoxifene is generally effective and safe in preventing bone loss and vertebral fracture in post-menopausal women with osteoporosis.

Singer A, Exuzides A, Spangler L, O’Malley C, Colby C, Johnston K et al., editors. Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. Mayo Clin Proc; 2015: Elsevier.

Detilleux J, Reginster JY, Chines A, Bruyere O. A Bayesian path analysis to estimate causal effects of bazedoxifene acetate on incidence of vertebral fractures, either directly or through non-linear changes in bone mass density. Stat Methods Med Res. 2016;25(1):400–12. https://doi.org/10.1016/j.bone.2017.01.024.CrossRefPubMed

Moreira LDF, MLd O, Lirani-Galvão AP, Marin-Mio RV, RNd S, Lazaretti-Castro M. Physical exercise and osteoporosis: effects of different types of exercises on bone and physical function of postmenopausal women. Arq Bras Endocrinol Metabol. 2014;58(5):514–22. https://doi.org/10.1590/0004-2730000003374.CrossRefPubMed

Curtis EM, Moon RJ, Harvey NC, Cooper C. The impact of fragility fracture and approaches to osteoporosis risk assessment worldwide. Bone. 2017;104:29–38. https://doi.org/10.1016/j.bone.2017.01.024.CrossRefPubMed

Christiansen C, Chesnut CH 3rd, Adachi JD, Brown JP, Fernandes CE, Kung AW, et al. Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis. BMC Musculoskelet Disord. 2010;11(1):130. https://doi.org/10.1186/1471-2474-11-130.CrossRefPubMedPubMedCentral

Ellis AG, Reginster JY, Luo X, Bushmakin AG, Williams R, Sutradhar S, et al. Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women. Curr Med Res Opin. 2014;30(8):1617–26. https://doi.org/10.1185/03007995.2014.908279.CrossRefPubMed

Silverman SL, Chines AA, Kendler DL, Kung AW, Teglbjaerg CS, Felsenberg D, et al. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2012;23(1):351–63. https://doi.org/10.1007/s00198-011-1691-1.CrossRef

Palacios S, de Villiers TJ, Nardone Fde C, Levine AB, Williams R, Hines T, et al. Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study. Maturitas. 2013;76(1):81–7. https://doi.org/10.1016/j.maturitas.2013.06.008.CrossRefPubMed

Xu B, Lovre D, Mauvais-Jarvis F. The effect of selective estrogen receptor modulators on type 2 diabetes onset in women: basic and clinical insights. J Diabetes Complications. 2017;31(4):773–779.https://doi.org/10.1016/j.jdiacomp.2016.12.010 CrossRefPubMed

10.

An K-C. Selective estrogen receptor modulators. Asian Spine Journal. 2016;10(4):787–91. https://doi.org/10.4184/asj.2016.10.4.787.CrossRefPubMedPubMedCentral

11.

Palacios S, Silverman SL, de Villiers TJ, Levine AB, Goemaere S, Brown JP, et al. A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture. Menopause. 2015;22(8):806–13. https://doi.org/10.1097/GME.0000000000000419.CrossRefPubMed

12.

Jover-Mengual T, Castelló-Ruiz M, Burguete MC, Jorques M, López-Morales MA, Aliena-Valero A, et al. Molecular mechanisms mediating the neuroprotective role of the selective estrogen receptor modulator, bazedoxifene, in acute ischemic stroke: a comparative study with 17β-estradiol. J Steroid Biochem Mol Biol. 2017;171:296–304. https://doi.org/10.1016/j.jsbmb.2017.05.001.CrossRefPubMed

13.

Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8(1):18. https://doi.org/10.1136/bmj.c332.CrossRefPubMedPubMedCentral

14.

Itabashi A, Yoh K, Chines AA, Miki T, Takada M, Sato H, et al. Effects of bazedoxifene on bone mineral density, bone turnover, and safety in postmenopausal Japanese women with osteoporosis. J Bone Miner Res : Off J Am Soc Bone Mineral Res. 2011;26(3):519–29. https://doi.org/10.1002/jbmr.252.CrossRef

15.

Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril. 2009;92(3):1045–52. https://doi.org/10.1016/j.fertnstert.2009.02.093.CrossRefPubMed

16.

Miller PD, Chines AA, Christiansen C, Hoeck HC, Kendler DL, Lewiecki EM, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res : Off J Am Soc Bone and Mineral Res. 2008;23(4):525–35. https://doi.org/10.1359/JBMR.071206.CrossRef

17.

Mirkin S, Komm BS, Pan K, Chines AA. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women. Climacteric : J Int Menopause Soc. 2013;16(3):338–46. https://doi.org/10.3109/13697137.2012.717994.CrossRef

18.

Pinkerton JV, Harvey JA, Lindsay R, Pan K, Chines AA, Mirkin S, et al. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab. 2014;99(2):E189–98. https://doi.org/10.1210/jc.2013-1707.CrossRefPubMed

19.

Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res : Off J Am Soc Bone Miner Res. 2008;23(12):1923–34. https://doi.org/10.1359/jbmr.080710.CrossRef

20.

Xu L, Tsai KS, Kim GS, Wu Y, Vincendon P, Chines AA, et al. Efficacy and safety of bazedoxifene in postmenopausal Asian women. Osteoporos Int : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2011;22(2):559–65. https://doi.org/10.1007/s00198-010-1259-5.CrossRef

21.

McClung MR. New management options for osteoporosis with emphasis on SERMs. Climacteric : J Int Menopause Soc. 2015;18(sup2):56–61. https://doi.org/10.3109/13697137.2015.1104010.CrossRef

22.

Maximov PY, Lee TM, Jordan VC. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol. 2013;8(2):135–55. https://doi.org/10.2174/1574884711308020006.CrossRefPubMedPubMedCentral

23.

Tabatabaei-Malazy O, Salari P, Khashayar P, Larijani B. New horizons in treatment of osteoporosis. DARU J Pharm Sci. 2017;25(1):2. https://doi.org/10.1186/s40199-017-0167-z.CrossRef

24.

Gatti D, Rossini M, Sblendorio I, Lello S. Pharmacokinetic evaluation of bazedoxifene for the treatment of osteoporosis. Expert Opin Drug Metab Toxicol. 2013;9(7):883–92. https://doi.org/10.1517/17425255.2013.794221.CrossRefPubMed

25.

McKeand W. Pharmacokinetics, dose proportionality, and bioavailability of bazedoxifene in healthy postmenopausal women. Clin Ther. 2017;39(9):1769–79. https://doi.org/10.1016/j.clinthera.2017.07.012.CrossRefPubMed

26.

Rossini M, Lello S, Sblendorio I, Viapiana O, Fracassi E, Adami S, et al. Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture. Drug Des Dev Ther. 2013;7:601–10. https://doi.org/10.2147/DDDT.S47807.CrossRef

27.

Reginster J-Y, Ferrari S, Hadji P. Current challenges in the treatment of osteoporosis: an opportunity for bazedoxifene. Curr Med Res Opin. 2014;30(6):1165–76. https://doi.org/10.1185/03007995.2014.890927.CrossRefPubMed

28.

Komm BS, Chines AA. Bazedoxifene: the evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosis. Ther Adv Musculoskelet Disease. 2012;4(1):21–34. https://doi.org/10.1177/1759720X11422602.CrossRef

29.

Komm BS, Morgenstern D, Yamamoto LA, Jenkins SN. The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women. Expert Rev Clin Pharmacol. 2015;8(6):769–84. https://doi.org/10.1586/17512433.2015.1099432.CrossRefPubMed

Titel: Effects of Bazedoxifene on Bone Mineral Density and Fracture in Post-Menopausal Osteoporotic Women: a Systematic Review and Meta-Analysis
verfasst von: Malahat Khalili
Ali Hosseinzadeh
Habib_ollah Mohammadi Kiavandani
Narges Khanjani
Publikationsdatum: 05.02.2018
Verlag: Springer US
Erschienen in: Clinical & Translational Metabolism / Ausgabe 1/2018
Print ISSN: 1534-8644
Elektronische ISSN: 2948-2445
DOI: https://doi.org/10.1007/s12018-018-9241-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Acknowledgement for Reviewers 2017

Glucocorticoid Excess in Bone and Muscle

Myokine—Irisin—and Its Effects Linking Bone and Muscle Function

Stress and Insufficiency Fractures

2018—Changing Times for CRBM